📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Mitochondria are double-membrane-bound organelles that are essential for cellular energy production. A fundamental question in eukaryotic cell biology is how the biogenesis of mitochondria is achieved and regulated

Lead Research Organisation: UNIVERSITY COLLEGE LONDON
Department Name: UNLISTED

Abstract

Mitochondria are key parts of the cell whose central role is to produce energy in a suitable form for many biological processes. They are also involved in programmed cell death, and in maintaining appropriate levels of calcium in cells. These activities require mitochondria to communicate with the cell nucleus. Disruption of mitochondrial function can lead to a broad range of human diseases including diabetes, neurodegenerative disorders, obesity, cancer and premature ageing. Therefore, a full understanding of the basic processes in mitochondria is needed to identify the causes and consequences of mitochondrial malfunction and to enable us to design new therapies that compensate for or correct such faults. This programme will study how mitochondria are made and how their function responds to the changing requirements of the cell during growth and development.

Technical Summary

Mitochondria are double-membrane-bound organelles that are essential for cellular energy production. A fundamental question in eukaryotic cell biology is how the biogenesis of mitochondria is achieved and regulated. The process requires the targeting, import and assembly of over 1500 proteins encoded in nuclear DNA. Because mitochondria also contain their own DNA (mtDNA), which in human contributes 13 key components of the energy production apparatus, bidirectional communication between the nucleus and the mitochondria is essential to produce the desired mitochondrial activity. Our knowledge of nucleus to mitochondria (anterograde) signalling pathways coordinating mitochondrial biogenesis is expanding rapidly, and is known to involve the actions of three factors: AMP kinase, Sirt1 and PGC1a. In contrast, the characterization of the key mitochondrial factors that contribute to the regulation of biogenesis, as well as factors involved in the retrograde response (signalling from mitochondria to the nucleus) is much more limited.

Recently my group has discovered a mitochondrial protein, MPV17, with the intrinsic capacity to stimulate mitochondrial function. MPV17 is an inner mitochondrial membrane protein of unknown function, which belongs to a small family of conserved proteins. In 2006, the identification of MPV17 as the gene responsible for a form of mitochondrial DNA depletion syndrome (MDS) linked its protein product to mtDNA maintenance in vivo. Mitochondrial DNA defects were established as a cause of human disease 25 years ago, and yet there is still much that remains obscure about mtDNA maintenance. In animals and plants almost nothing is known about the anchoring, segregation or transmission of mtDNA. Furthermore, mitochondrial (DNA) dysfunction is also implicated in several common disorders, such as neurodegenerative disease, metabolic syndrome and obesity. Thus the functional characterization of proteins causing mitochondrial disease, such as MPV17, is critical to a full understanding of the role of mitochondria in human health, and the design of rational therapeutic strategies. An ability to stimulate mitochondrial biogenesis is widely recognised as the best immediate prospect for treating mitochondrial dysfunction. Hence, the new finding of MPV17’s effect on mitochondrial biogenesis provides a major new target for this approach, which will be best exploited with knowledge of its mechanism of action.

The plan is to elucidate MPV17’s mechanism of action by dissecting the protein and its partners, studying its pathological variants and the regulation of MPV17 gene expression. Specific aims are: 1) To determine the functional and physiological impacts of MPV17 ablation and mutation via proteomic and metabolite profiling of mutant cell lines and an Mpv17 knockout mouse. Fibroblast deficient cell lines, DG75 mutant and a knockout mouse model for MPV17 are already providing us with material for analysis, and they will be used in the future for transcriptomic, proteomic and metabolomic analyses, and for interventions designed to ameliorate its loss. 2) To characterize MPV17’s protein partners by affinity purification and use truncated forms of the protein to identify the key elements needed for these protein-protein interactions. 3) To dissect the stimulatory effects of MPV17 on mitochondrial biogenesis via metabolic, proteomic, and ultrastructure analyses.

Our studies of MPV17 have led to the realization that the metabolic conditions for cell growth have a major impact on mitochondrial function. We have identified nutrient growth regimes that stimulate mitochondrial protein synthesis while repressing protein synthesis in the cytosol. Therefore we predict that some mechanisms of stimulating mitochondrial capacity will repress cytosolic protein synthesis and thereby arrest cell growth and division.

Publications

10 25 50
publication icon
Aiestaran-Zelaia I (2022) 2 deoxy-D-glucose augments the mitochondrial respiratory chain in heart. in Scientific reports

publication icon
Baechler SA (2019) Beyond the unwinding: role of TOP1MT in mitochondrial translation. in Cell cycle (Georgetown, Tex.)

publication icon
Durigon R (2018) LETM1 couples mitochondrial DNA metabolism and nutrient preference. in EMBO molecular medicine

 
Description Bologna, Italy
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a guidance/advisory committee
Impact PMID: 32898308
 
Description ENMC, Heemskerk, The Netherlands.
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a guidance/advisory committee
 
Description Detecting Cholesterol in Biological Membranes in Vivo: a new tool for biomedicine
Amount £55,000 (GBP)
Organisation MRC Harwell 
Sector Academic/University
Country United Kingdom
Start 08/2023 
End 10/2025
 
Description Mitochondrial Medicine call_ research grant
Amount € 383,944 (EUR)
Funding ID Application Number: 28492 
Organisation French Muscular Dystrophy Association (AFM) 
Sector Charity/Non Profit
Country France
Start 01/2025 
End 12/2027
 
Description Quality control of the Mitochondrial Gene Expression System in health and disease
Amount £2,600,000 (GBP)
Organisation Marie Sklodowska-Curie Actions 
Sector Charity/Non Profit
Country Global
Start 09/2022 
End 09/2027
 
Title Generation of Induced Pluripotent Stem Cells (iPSCs) 
Description iPSCs have been generated from fibroblasts derived from patients with mitochondrial DNA disorders, PD and healthy controls 
Type Of Material Cell line 
Year Produced 2021 
Provided To Others? No  
Impact The iPSCs have been differentiated into the neuronal cells that are more affected in PD. An initial characterization has demonstrated the cells manifest a marked phenotype. Further study will be crucial to unravel the role of mitochondrial DNA in the onset and progression of PD pathology 
 
Title New sequencing method 
Description The new method is able to determine the identity of the embedded ribonucleotides incorporated in DNA. We have used the new method to study the ribonucleotide incorporation in mitochondrial DNA in health and disease state. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact The method has allowed the identification of a new mtDNA abnormality, which we predict to be a feature of many disorders in which mitochondrial function is impaired 
 
Title Nucleotide measurement 
Description AS group has developed a novel non-radioactive method for precise measurement of DNA synthesis building blocks (nucleotides) in both the cytosol and mitochondria. The scientists have validated its accuracy by comparing results with the established radioactive assay. 
Type Of Material Technology assay or reagent 
Year Produced 2023 
Provided To Others? No  
Impact This method has enabled the researchers to measure the levels of nucleotides in tissues of mice subjected to potential therapeutic interventions identified by AS group. The results are included in a manuscript submitted for publication to a high-profile journal. The new method is also used to assess the effect of the small molecules that select mtDNA on the nucleotide pool. The expectation is that the method efficiency and reliability will lead to its widespread adoption. 
 
Title Small molecules 
Description Identification of small molecules that purge the cells of mutant mitochondrial genome and restore mitochondrial function. 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? Yes  
Impact One of the molecules tested in control animals has shown promising results in increasing mitochondrial functionality. Currently, we are conducting further testing in cells carrying various types of mutated mitochondrial DNA and in mouse models of disease to evaluate its efficacy in relevant contexts. Additionally, our team is in the process of preparing a clinical trial to assess the effects of this compound on a cohort of patients with mitochondrial DNA disorders. This represents an important step towards translating our preclinical findings into potential therapeutic interventions for human diseases. Finally, our team recently published a comprehensive review on this topic in a high-profile journal, consolidating the current understanding of mitochondrial DNA disorders and highlighting potential therapeutic strategies. 
 
Title small molecules 
Description Identification of small molecules that purge the cells of mutant mitochondrial genome and restore mitochondrial function 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? Yes  
Impact One of the molecules tested in control animal increases mitochondrial functionality. Currently, the team is preparing a clinical trial to test the effect of the compound on a cohort of patients with mitochondrial DNA disorders. 
 
Description Assessing the effect of small molecules on liver pathology 
Organisation University College London
Department UCL Cancer Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution AS group has supplied liver tissues sourced from control mice and genetically modified animals presenting mitochondrial DNA dysfunction. These mice have been subjected to treatment with either vehicle or small molecules that are able to restore mitochondrial DNA levels and mitochondrial activities.
Collaborator Contribution Histopathological assessment of the liver samples.
Impact Although histological alterations are evident in the defective mice only when they age, they are reversed by the treatment. A manuscript detailing these findings has been submitted for publication to a high-profile journal.
Start Year 2023
 
Description Elucidating the function of MPV17p 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution We isolated RNA from Mpv17 WT and KO mouse tissues
Collaborator Contribution Transcriptomic analysis of Mpv17 WT and KO mouse tissues
Impact Signalling pathways and compensatory mechanisms associated to the tissue-specific Mpv17 dysfunction
Start Year 2016
 
Description Elucidating the role of Mpv17 in nucleotide metabolism 
Organisation Vall d'Hebron University Hospital
Country Spain 
Sector Hospitals 
PI Contribution Tissues and mitochondria from Wt and Mpv17 KO mice
Collaborator Contribution Analysis of mitochondrial subfractions
Impact Abstract for meetings. Consortium organization for the study of mitochondrial DNA depletion and deletions Syndromes.
Start Year 2018
 
Description Investigating the effect of mitochondrial dysfunction on the liver- brain axis 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution AS group has supplied brain tissues obtained from both control mice and mice genetically modified, which present mitochondrial DNA dysfunction.
Collaborator Contribution Histopathological analysis of specific brain regions implicated in the regulation of insulin signaling
Impact The collaboration has commenced recently, outcomes are expected within the forthcoming months.
Start Year 2024
 
Description Ion metabolism and mitochondrial DNA replication 
Organisation Great Ormond Street Hospital (GOSH)
Department Dubowitz Neuromuscular Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution Identification of novel factors regulating mitochondrial DNA metabolism
Collaborator Contribution The collaborators have provided cells (patient-derived fibroblasts) carrying mutations in factors involved in ion homeostasis.
Impact Preliminary data indicate that the mutants display perturbation of mtDNA homeostasis. If confirmed, this can lead to a major breakthrough with important medical implication.
Start Year 2024
 
Description Measurement of metabolites 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Tissues samples from WT and Mpv17 KO mice
Collaborator Contribution Determination of metabolites in several tissues
Impact The effect of mtDNA perturbation on cellular metabolism
Start Year 2018
 
Description Metabolites measurement 
Organisation University College London
Department Neurometabolic Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution AS group has provided tissues obtained from control mice and transgenic mice presenting mitochondrial DNA dysfunction. The mice have been subjected to treatment with either vehicle or small molecules; the latter restore mitochondrial DNA levels and mitochondrial activities.
Collaborator Contribution Determination of metabolites in tissues from treated and untreated animals.
Impact Mice with mitochondrial DNA dysfunction display marked changes in the liver metabolism; importantly, these changes are restored by the treatment.
Start Year 2023
 
Description Molecular basis of mitochondrial disorders 
Organisation Murdoch Children's Research Institute
Country Australia 
Sector Academic/University 
PI Contribution Characterization of the cellular and mitochondrial metabolism in cells derived from patients with mutations in a new causative gene of mitochondrial disease.
Collaborator Contribution Identification of a new genetic cause of mitochondrial disorders. Fibroblasts from mutant patients.
Impact Cholesterol and mtDNA metabolisms are co-regulated. Papers in high profile journal.
Start Year 2016
 
Description Molecular basis of mitochondrial disorders 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. Papers in high profile journal
Start Year 2016
 
Description Molecular basis of mitochondrial myopathy 
Organisation Newcastle University
Department Mitochondrial Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution In situ analysis of mtDNA distribution and the cellular response to mitochondrial DNA instability
Collaborator Contribution Providing muscle biopsy from subjects with mtDNA disorders and controls
Impact Identification of processes and pathways supporting the genesis and propagation of mutant mtDNA. Publication in journal of high profile.
Start Year 2019
 
Description Molecular basis of mitochondrial myopathy 
Organisation Newcastle University
Department Wellcome Trust Centre for Mitochondrial Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Muscle samples from WT and KO mice
Collaborator Contribution Histology and Immunohistochemistry
Impact Time course of muscle pathology in a murine model of a mtDNA related disoder
Start Year 2018
 
Description New causative genes of mitochondrial disorders 
Organisation Newcastle University
Department Wellcome Trust Centre for Mitochondrial Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. PMID: 31600844 PMID: 36055214 PMID: 33742325 PMID: 31039582
Start Year 2017
 
Description New causative genes of mitochondrial disorders 
Organisation Ospedale Pediatrico Bambino Gesu (OPBG)
Country Italy 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. PMID: 31600844 PMID: 36055214 PMID: 33742325 PMID: 31039582
Start Year 2017
 
Description New causative genes of mitochondrial disorders 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Characterization of the biochemical and molecular phenotypes in patient-derived cells and tissues
Collaborator Contribution The partners have identified new genes likely causative of human disorders. They have provided cell lines and tissues from affected patients
Impact Changes in mitochondrial metabolism supportive of the functional role of the causative genes. PMID: 31600844 PMID: 36055214 PMID: 33742325 PMID: 31039582
Start Year 2017
 
Description Nucleoside-based therapy for mtDNA disorders 
Organisation Zogenix Inc
Department Modis Therapeutics
Country United States 
Sector Private 
PI Contribution Testing the effect of modified molecules on mtDNA dysfunction in a mouse model of mtDNA depletion
Collaborator Contribution Developed modified compounds that increase in vivo bioaviability
Impact Ongoing analysis
Start Year 2019
 
Description Pathophysiological consequences of mitochondrial DNA replication defects 
Organisation Helmholtz Association of German Research Centres
Department Helmholtz Zentrum Munchen
Country Germany 
Sector Academic/University 
PI Contribution Identification of calcium-related pathways as dysfunctional in in vivo and in vitro models of mitochondrial DNA disorders.
Collaborator Contribution Measurement of the mitochondrial calcium uptake in a mouse model of mitochondrial DNA dysfunction
Impact Dysfunctional mitochondria uptake more calcium than functional organelles. A manuscript describing the findings has been submitted for publication to a high-profile journal.
Start Year 2022
 
Description Pharmacological manipulation of mitochondrial DNA selection 
Organisation Newcastle University
Department Newcastle University Medical School
Country United Kingdom 
Sector Academic/University 
PI Contribution Identification of small molecules that select functional mitochondrial genomes
Collaborator Contribution Providing cells from patients with mitochondrial DNA disorders
Impact Publication, PMID:34873176 Patent, GB2116499.1.
Start Year 2016
 
Description Pharmacological manipulation of mitochondrial DNA selection 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Identification of small molecules that select functional mitochondrial genomes
Collaborator Contribution Providing cells from patients with mitochondrial DNA disorders
Impact Publication, PMID:34873176 Patent, GB2116499.1.
Start Year 2016
 
Description Physiopathology of mtDNA disorders 
Organisation Centre for Cooperative Research in Biomaterials (CIC BiomaGUNE)
Country Spain 
Sector Academic/University 
PI Contribution 1)Pathological characterization of a mouse model of mtDNA disorder 2) Identification of a small molecule ( 2-Deoxy-D-Glucose, 2DG) that promote the propagation of the functional mitochondrial DNA in models of disorders where mutant and wild-type mitochondrial genomes coexist.
Collaborator Contribution Imagining in an in vivo model of mtDNA disorders Imaging and tissues analyses of control mice treated with 2DG
Impact -Publication, PMID:35478201 -The collaboration involves molecular biology, imaging, omic studies (proteomic)
Start Year 2019
 
Description Ribonucleotide incorporation in mtDNA 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Purified mtDNA from mouse tissues and culture cells for sequencing analysis
Collaborator Contribution Sequencing of the mtDNA using a new approach developed by the collaborators (Emboriboseq) and analysis of the data
Impact Identification of the identity and distribution of the ribonucleotide incorporated in mtDNA of normal tissues and cells. Identification of a new mtDNA abnormality, aberrant ribonucleotide incorporation, in tissues of the Mpv17 KO mouse. Paper in journal of high profile (PMID:29106596)
Start Year 2016
 
Title COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS 
Description There is described a compound for use in the treatment of a mitochondrial DNA disorder, wherein the compound is a glycolysis inhibitor, an inhibitor of glutamine consumption or is L-asparaginase or pegaspargase. The glycolysis inhibitor may be a glucose analogue such as 2-deoxy-D-glucose (2DG) or 5-thioglucose (5TG). Also described is a method of treating a mitochondrial DNA disorder comprising administering a therapeutically effective amount of the compound above to a patient suffering from a mitochondrial DNA disorder. In addition, there is described a method of reducing the mtDNA heteroplasmy in the cells of a patient comprising administering a therapeutically effective amount of the compound above to the patient. 
IP Reference US2025017950 
Protection Patent / Patent application
Year Protection Granted 2025
Licensed Commercial In Confidence
 
Title Compounds for the treatment of heteroplasmic mitochondrial DNA disorders 
Description Compounds for the treatment of mitochondrial DNA disorders 
IP Reference GB2116499.1. 
Protection Patent application published
Year Protection Granted 2021
Licensed No
Impact Pharmacompanies are interested in licensing the patent. This could lead to investments on basic research and clinical trials
 
Title 2-deoxy-D-glucose 
Description The compound has been investigated in several preclinical and clinical studies, but never tested in patients with mitochondrial disorders. A source of the drug has been identified and a clinical trial is in preparation. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2018
Development Status On hold
Impact The product is in development 
 
Description Aspire bioscience event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact The aim of the meeting was to facilitate networking between rare disease groups- represented by patient organizations members and scientific-medical support- and drug development companies. The meeting was well structured and intense and planted the seed for future interactions between the parties. Follow-up meetings with specific companies have resulted in novel collaboration to test potential therapeutic strategies AS research group is developing.
Year(s) Of Engagement Activity 2023,2024
 
Description ENMC, Heemskerk, The Netherlands. 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The 232nd ENMC International Workshop held in Heemskerk, The Netherlands in June 2017. Among the participant were expert in the field of mDNA metabolism, relatives of patients and members of biopharmaceutical companies. The aims of the workshop were to identify actions needed to advance the clinical recognition, diagnosis, and treatment of patients suffering from disorders of mtDNA maintenance. Clear guidelines were issued.
Year(s) Of Engagement Activity 2017
 
Description Gdansk, 17th symposium on Purine and Pyrimidine in Man 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I was invited to give a presentation as leader in the field in mtDNA disorders. The new findings stimulated interest in the research topic. Novel collaborations started after the meeting.
Year(s) Of Engagement Activity 2017
 
Description Invited speaker at an International scientific meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS presented the progress her group has made in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2022
 
Description Invited speaker at an International scientific meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS presented her group progress in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2022
 
Description MEET final meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact My group organized the final event of the Mitocondrial European Education and Training (MEET) in London ( 12 Dec 2016).

The event included a scientific conference with eminent speakers from the mitochondria - and non - community, and a dissemination part.
Year(s) Of Engagement Activity 2016
 
Description Patient group workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact AS presented, during an online meeting, the group progress in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2020
 
Description Seminar to Neurological Institute Besta 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS presented, during an online meeting, the group progress in developing potential treatments for mitochondrial DNA disorders.
Year(s) Of Engagement Activity 2022
 
Description UK Neuromuscular Translational Research Conference 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AS was invited to give a presentation on her latest research on mtDNA selection and one of her fellow was selected for a poster presentation.
Both presentations stimulated increased interest in the research topic.
Year(s) Of Engagement Activity 2019
 
Description Udine _ First MITGEST workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact As a recognized leader in the field of mitochondrial genomic instability, she was invited to present on the topic. During her presentation, AS shared her group's research findings on a potential treatment developed for a group of mitochondrial disorders. She also took the opportunity to share her personal research journey with the student audience. The talk sparked a lively discussion and generated numerous questions afterward. She was pleased to learn that her presentation was viewed as inspirational by the audience, particularly by the younger generation. Furthermore, she received invitations from two other Principal Investigators present at the meeting to give a presentation at an EMBO meeting scheduled to take place in Poland in May 2024. This invitation is a testament to the impact of her work and its relevance to the broader scientific community.
Year(s) Of Engagement Activity 2023